freddifish, page-3

So, Avexa's drug is "one of the most exciting unpartnered HIV drugs in development"?

How many are there? Hundreds? (Of unpartnered HIV drugs.) And, not to put a dampener on things, but saying "one of" means that there is no standout candidate. Which is fine, although somewhat of a cop-out.

I'm still a buyer at these discounted levels, but you have to wonder about analysts which make such double-edged statements. At this stage of the game, Avexa's only competitor is, surprisingly, itself.